Literature DB >> 25224916

Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study.

Megan A Healey1, Rong Hu, Andrew H Beck, Laura C Collins, Stuart J Schnitt, Rulla M Tamimi, Aditi Hazra.   

Abstract

Repressive histone tail modifications have been associated with molecular breast cancer subtypes. We investigated whether histone 3 lysine 9 trimethylation (H3K9me3) and histone 3 lysine 27 trimethylation (H3K27me3) were associated with tumor features and subtypes while adjusting for prospectively collected reproductive and lifestyle breast cancer risk factors. We have tissue microarray data with immunohistochemical marker information on 804 incident cases of invasive breast cancer diagnosed from 1976-2000 in the Nurses' Health Study. Tissue microarray sections were stained for global H3K9me3 and H3K27me3, and scored into four categories. Multivariate odds ratios (OR) and 95 % confidence intervals (CI) were calculated using logistic regression models for tumor features and subtypes, adjusting for breast cancer risk factors. While there were no significant associations between H3K9me3 and tumor features, H3K27me3 was significantly associated with lower grade tumors compared to high grade tumors in the multivariate model (OR = 1.95, 95 % CI 1.35-2.81, p = 0.0004). H3K27me3 was suggestively associated with estrogen receptor-positive (ER+) tumors (OR = 1.47, 95 % CI 0.97-2.23, p = 0.07). In subtype analyses, H3K27me3 was positively associated with the luminal A subtype compared to all other subtypes (OR = 1.42, 95 % CI 1.14-1.77, p = 0.002), and was inversely associated with HER2-type (OR = 0.58, 95 % CI 0.37-0.91, p = 0.02) and basal-like breast cancer (OR = 0.52, 95 % CI 0.36-0.76, p = 0.0006). In the largest immunohistochemical examination of H3K9me3 and H3K27me3 in breast cancer, we found that H3K27me3 positivity, but not H3K9me3, was associated with lower grade tumors and the luminal A subtype after adjusting for reproductive and lifestyle breast cancer risk factors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224916     DOI: 10.1007/s10549-014-3089-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  26 in total

Review 1.  Epigenetic regulation of DNA repair machinery in Helicobacter pylori-induced gastric carcinogenesis.

Authors:  Juliana Carvalho Santos; Marcelo Lima Ribeiro
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

2.  HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.

Authors:  Sylvia Mahara; Puay Leng Lee; Min Feng; Vinay Tergaonkar; Wee Joo Chng; Qiang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-14       Impact factor: 11.205

3.  Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.

Authors:  Megan A Healey; Kelly A Hirko; Andrew H Beck; Laura C Collins; Stuart J Schnitt; A Heather Eliassen; Michelle D Holmes; Rulla M Tamimi; Aditi Hazra
Journal:  Breast Cancer Res Treat       Date:  2017-08-08       Impact factor: 4.872

4.  Methylation Patterns of Lys9 and Lys27 on Histone H3 Correlate with Patient Outcome in Gastric Cancer.

Authors:  Yiping Li; Didi Guo; Rui Sun; Ping Chen; Qi Qian; Hong Fan
Journal:  Dig Dis Sci       Date:  2018-10-22       Impact factor: 3.199

Review 5.  Genomics, Telomere Length, Epigenetics, and Metabolomics in the Nurses' Health Studies.

Authors:  Mary K Townsend; Hugues Aschard; Immaculata De Vivo; Karin B Michels; Peter Kraft
Journal:  Am J Public Health       Date:  2016-07-26       Impact factor: 9.308

6.  Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples.

Authors:  Roberta Noberini; Andrea Uggetti; Giancarlo Pruneri; Saverio Minucci; Tiziana Bonaldi
Journal:  Mol Cell Proteomics       Date:  2015-10-13       Impact factor: 5.911

7.  The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer.

Authors:  Seher Karsli-Ceppioglu; Aslihan Dagdemir; Gaëlle Judes; André Lebert; Frédérique Penault-Llorca; Yves-Jean Bignon; Dominique Bernard-Gallon
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

8.  PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples.

Authors:  Roberta Noberini; Rémi Longuespée; Cristina Richichi; Giancarlo Pruneri; Mark Kriegsmann; Giuliana Pelicci; Tiziana Bonaldi
Journal:  Clin Epigenetics       Date:  2017-07-11       Impact factor: 6.551

9.  miR-125b-1 is repressed by histone modifications in breast cancer cell lines.

Authors:  Fernanda Cisneros-Soberanis; Marco A Andonegui; Luis A Herrera
Journal:  Springerplus       Date:  2016-07-02

10.  Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis.

Authors:  Michel Wassef; Veronica Rodilla; Aurélie Teissandier; Bruno Zeitouni; Nadege Gruel; Benjamin Sadacca; Marie Irondelle; Margaux Charruel; Bertrand Ducos; Audrey Michaud; Matthieu Caron; Elisabetta Marangoni; Philippe Chavrier; Christophe Le Tourneau; Maud Kamal; Eric Pasmant; Michel Vidaud; Nicolas Servant; Fabien Reyal; Dider Meseure; Anne Vincent-Salomon; Silvia Fre; Raphaël Margueron
Journal:  Genes Dev       Date:  2015-12-04       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.